Associate Scientist / Immunology/Cell Biology

Research & Development San Diego, California



  • IPO, clinical stage biotech with lead asset in Ph 1 and potential for first-in-class mechanism
  • First precision medicine approach to GI therapeutics, with platform attracting strong partners
  • Global exclusive license to Cedars-Sinai’s GI biobank and bioinformatics platform
  • Fully capitalized with top-tier investor syndicate

Prometheus is a IPO biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD). The company's precision medicine platform, Prometheus 360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is a spin out of Cedars-Sinai Medical Center and partners with the hospital system for its biospecimens, clinical data, and bioinformatics.

The company is led by an exceptional management team bringing deep experience in GI and autoimmune therapies. CEO Mark McKenna joined in 2019 to refocus the organization around a precision therapeutics strategy after orchestrating a successful turnaround effort at Salix Pharmaceuticals. Mark and the executive team are guided by Prometheus’ board of directors, led by Chairman Tachi Yamada, M.D., and a scientific advisory board composed of key opinion leaders in IBD, including Stephan Targan, M.D., William Sandborn, M.D. and Dermot P. McGovern, M.D., Ph.D.

The company recently secured a $130 million Series D financing with a top-tier syndicate and is attracting best-in-class collaboration partners such as Takeda and Dr. Falk. With a lead therapeutic program in Phase 1 studies and a robust emerging pipeline, the company is seeking a best-in-class immunologist to lead all of Prometheus’ preclinical development efforts and be accountable for delivering a sustainable pipeline of drug candidates, from target validation through IND submission.


We seek a motivated, detail-oriented Associate Scientist with strong background in immunology / cell biology and experience developing cell-based assays to support our efforts in target validation, early phase antibody drug discovery, IND-enabling studies, biomarker discovery and companion diagnostics development. The ideal candidate is an individual that enjoys a fast-paced and dynamic work environment, with a demonstrated ability to work collaboratively to support project goals and objectives. 


  • Develop and perform cell-based functional assays (cell lines, primary cells, whole blood) to support target validation, antibody drug screening, mechanism of action studies, biomarker identification and/or companion diagnostics development
  • Analyze, critically interpret data and share results to project teams as required
  • Keep meticulous records of experiments performed and maintain ELN entries
  • Act as a resource for other scientists in the group



  • BS degree in a biological science required.
  • 6 years or more of hands-on lab experience in an industry drug discovery / development setting is required.
  • Strong cell culture skills and assay development experience are essential.
  • Experience developing ex vivo models to assess immune responses in human whole blood, PBMCs and various cell subsets (T cells, NK cells, etc) is required
  • Experience using multi-color flow cytometry to characterize immune cell phenotype (extracellular and intracellular markers) and target engagement is required
  • Experience using MSD, Luminex and ELISA to measure analytes in serum, plasma, supernantant or cell lysates is required
  • Experience developing luciferase reporter assays is required
  • Proficiency in data analysis using Excel and GraphPad Prism is requried.

All qualified applicants are considered for employment without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability, veteran status or other protected class.